Canaccord Genuity Maintains Buy on Beam Therapeutics, Lowers Price Target to $78
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Whitney Ijem maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $79 to $78.
Canaccord Genuity analyst Whitney Ijem maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $79 to $78.